论文部分内容阅读
目的观察奥沙利铂联合卡培他滨治疗ECOG评分0~1分初治晚期结直肠癌的疗效和安全性。方法 54例ECOG评分0~1分初治晚期结直肠癌患者应用奥沙利铂130 mg/m2,静脉滴注2 h,d1;卡培他滨1000 mg/m2,口服,2次/d,d1~14;每21 d为1个周期。可评价疗效的患者需至少接受2个周期治疗,每2个周期结束后进行疗效评价。结果全组54例患者均可评价疗效,其中CR 3例,PR 27例,SD 18例,PD 6例,全组有效率55.6%,总生存期19.7个月,无进展生存期7.7个月。不良反应主要为Ⅰ~Ⅲ度神经毒性、腹泻、骨髓抑制、黏膜炎、手足综合征等,没有因不良反应中止化疗或致死的病例。结论奥沙利铂联合卡培他滨治疗ECOG评分0~1分初治晚期结直肠癌疗效显著,耐受性良好,患者生活质量改善,效价比明显提高,该方案值得在临床中进行推广。
Objective To observe the efficacy and safety of oxaliplatin plus capecitabine in the treatment of advanced colorectal cancer with ECOG score of 0 ~ 1. Methods Fifty-four patients with advanced colorectal cancer who had ECOG score of 0 to 1 were treated with Oxaliplatin 130 mg / m2, intravenous drip 2 h, d1, capecitabine 1000 mg / m2 orally, twice daily, d1 ~ 14; Every 21 d is 1 cycle. Evaluable efficacy of patients receiving at least 2 cycles of treatment, the efficacy evaluation after the end of each 2 cycles. Results All the 54 patients could evaluate the curative effect. Among them CR 3 cases, PR 27 cases, SD 18 cases and PD 6 cases, the total effective rate was 55.6%, the total survival time was 19.7 months and the progression-free survival time was 7.7 months. Adverse reactions mainly Ⅰ ~ Ⅲ degree neurotoxicity, diarrhea, myelosuppression, mucositis, hand-foot syndrome, etc., no adverse reactions to chemotherapy or lethal cases. Conclusion oxaliplatin combined with capecitabine in treatment of advanced colorectal cancer with ECOG score of 0 ~ 1 is effective and well tolerated, the quality of life of patients is improved, the price-effectiveness ratio is significantly improved, and the scheme deserves promotion in clinical practice .